Group 1: Plasma Source and Quality Control - The company implements a strategy of incremental cultivation and potential excavation for plasma source development, setting annual plasma collection targets based on previous year's data and company strategy [2] - A comprehensive blood plasma quality management system has been established, with a strong emphasis on digital regulatory system construction to ensure the safety of raw plasma quality [2] - The "Pingguo Experience" is a long-term accumulated work experience that optimizes the entire plasma collection process, which is promoted across other plasma stations to enhance service levels [2] Group 2: Plasma Collection Stations and Growth - The company currently operates 9 plasma collection stations, with a sustained growth in plasma collection scale in recent years [3] - The average plasma collection volume at the stations is leading in the industry, with the Pingguo station showing continuous growth [3] - The company holds 11 product varieties across 3 major categories, achieving a high comprehensive utilization rate of plasma [3] Group 3: Market Position and Strategic Response - The blood product market in China still has significant growth potential compared to mature markets in Europe and the U.S., despite challenges from recombinant products [4] - The company plans to enhance R&D capabilities to introduce more new products, maintaining a focus on traditional blood-derived products [4] - The company actively monitors industry dynamics to identify new profit growth points while solidifying its core blood product business [3] Group 4: Research and Development Projects - Recent achievements include obtaining registration certificates for human coagulation factor VIII and prothrombin complex, with ongoing key projects in various blood-related products [4] - R&D investment is determined based on strategic planning and project progress, ensuring effective allocation of resources [4] Group 5: Market Share and Brand Competitiveness - The company adopts market-oriented sales strategies tailored to different products, continuously improving its marketing system and building a professional sales team [4] - Efforts are made to expand new sales channels while deepening cooperation with relevant parties to enhance international visibility and brand influence [4]

Group 1 - The company has nominated Huang Juan as an independent director candidate for its fourth board of directors, confirming her independence and compliance with relevant regulations [1][2][3] - Huang Juan has undergone qualification review by the company's nomination committee and has no relationships that could affect her independent performance [1][2] - The candidate has confirmed that she meets the qualifications and conditions set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange for independent directors [2][3][4] Group 2 - The company has also nominated Zhang Jianping as an independent director candidate, who has agreed to the nomination and confirmed his independence [29][58] - Zhang Jianping has passed the qualification review and has no conflicts of interest that could impact his independent duties [29][58] - The nomination is based on a thorough understanding of Zhang Jianping's professional background, qualifications, and absence of any significant credit issues [29][58]

Core Viewpoint - Shenzhen Weiguang Biological Products Co., Ltd. is undergoing a board re-election process in accordance with relevant laws and regulations, with the nomination of candidates for the fourth board of directors [1][2]. Group 1: Board Election Process - The third board of directors held its thirty-fourth meeting on July 1, 2025, and approved the proposals for the re-election of the board and the nomination of candidates for both non-independent and independent directors [2]. - The candidates for the fourth board include five non-independent directors and three independent directors, with their qualifications having been reviewed by the board's nomination committee [2][3]. - The election will be conducted at the company's first extraordinary general meeting of 2025, using a cumulative voting system to elect eight directors, alongside one employee representative director [2][3]. Group 2: Candidate Qualifications - Zhang Zhan, the current chairman, has a graduate degree and is a senior engineer, with a history of serving in various roles within the company [3][4]. - Guo Caiping, the current general manager, holds a doctoral degree and has been with the company since 1994, having held multiple positions [5][6]. - Chen Guanqun, the financial director, is a senior accountant with a bachelor's degree in economics and has experience in various financial roles [6][7]. - Li Ligan, a current director, has a bachelor's degree and serves as the financial director at another company [7][8]. - Zhang Xianen, a biotechnology expert, has extensive academic qualifications and has held significant positions in research institutions [8][9]. - The independent director candidates, including Wang Yanmei, Huang Juan, and Zhang Jianping, have relevant academic and professional backgrounds, ensuring they meet the independence criteria [9][10].

深圳市卫光生物制品股份有限公司 序号 修订前 修订后 第一条 为维护公司、股东和债权人的合法权益，规范公司的组 第一条 为维护公 司、股东、职工和债权人的合法权益，规范公司的组织和行 织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》） 《中 为，根据《中华人民共和国公司法》 （以下简称《公司法》） 《中华人民共和国证券法》 华人民共和国证券法》（以下简称《证券法》）《中国共产党章程》（以 （以下简称《证券 法》） 《中国共产党章程》（以下简称《党章》） 和其他有关规定， 下简称《党章》 ）和其他有关规定，制订本章程。 制订本章程。 第八条 董事长为公司的法定代表人。 董事长辞任的，视为同时辞去法定代表人。 董事长辞任或者不再担任法定代表人的，在选任新任 董事长之前，由总经理兼 法定代表人以公司名义从事的民事活动，其法律后果 由公司承受。本章程或者 股东会对法定代表人职权的限制，不得对抗善意相对 人。 担民事责任。公司承担民 的法定代表人追偿。 任，公司以其全部财产对公司 第九条 公司全部资产分为等额股份，股东以其认购的股份为限 对公司承担责任，公司以其全部资产对公司的债务承担责任。 第十四条 经依 ...

Core Viewpoint - Shenzhen Weiguang Biological Products Co., Ltd. has revised its Articles of Association and related systems to enhance corporate governance and operational standards [1][2]. Group 1: Articles of Association Revision - The company has proposed amendments to its Articles of Association to improve governance structure and comply with relevant laws and regulations [1]. - The revised Articles of Association and a comparison table of changes are available on the official website [1]. Group 2: Related System Revisions - The board of directors has approved revisions to several internal systems, including those related to independent directors, audit committee, nomination committee, compensation and assessment committee, strategic committee, insider information management, and accountant selection [1]. - The full text of the revised systems is also published on the official website [1].

Core Points - The company has approved the implementation of the third employee stock ownership plan [1][2] - The lock-up period for the employee stock ownership plan will expire on July 7, 2025 [1] - The plan has completed the purchase of company shares through the secondary market as of July 3, 2024 [1] Summary of Employee Stock Ownership Plan - The employee stock ownership plan will have a lock-up period of 12 months from the date of the last share transfer [1] - After the lock-up period, the management committee will decide on the timing of selling the shares held by the plan [1][2] - The plan will comply with market trading rules and relevant laws and regulations [1] Duration, Changes, and Termination of the Plan - The duration of the employee stock ownership plan starts from the date of the last share transfer to the plan [2] - Changes to the plan require approval from at least two-thirds of the participating holders [2] - The plan can be terminated early under certain conditions, including the inability to liquidate all shares before the expiration of the duration [2]

Core Viewpoint - The independent director candidate Wang Yanmei has declared her commitment and qualifications to serve on the fourth board of Shenzhen Weiguang Biological Products Co., Ltd, ensuring her independence and compliance with relevant regulations [1][2][3]. Group 1 - The candidate has confirmed that there are no relationships with the company that could affect her independence [1]. - The candidate has passed the qualification review by the company's nomination committee and has no conflicts of interest with the nominator [1]. - The candidate meets the qualifications and conditions for independent directors as stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange [1][2]. Group 2 - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2]. - The candidate has no violations of laws or regulations that would disqualify her from serving as an independent director [2][3]. - The candidate has the necessary knowledge and experience related to the operation of listed companies, with over five years of relevant work experience [3][4]. Group 3 - The candidate and her immediate family do not hold any shares in the company or its subsidiaries [4][5]. - The candidate has not been subject to any disqualifications or penalties by regulatory authorities in the past three years [5][6]. - The candidate has committed to report any changes in her qualifications during her tenure as an independent director [6][7].

第一条 为更好地管理深圳市卫光生物制品股份有限公司（以下简称公司） 生产经营工作，促进公司经营管理的制度化、规范化、科学化，确保公司重大生 产经营决策的正确性、合理性，提高民主决策、科学决策水平，以使公司的生产 经营高效有序进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《公司章程》有关规定，并结合公司的实际情况，制定本细则。 第二条 本细则对公司总经理、副总经理和其他高级管理人员的职责权限与 工作分工、主要管理职能作出规定。 第三条 公司总经理、副总经理及其他高级管理人员除应按《公司章程》的 规定行使职权外，还应按照本细则的规定行使管理职权并承担管理责任。 深圳市卫光生物制品股份有限公司 总经理工作细则 第一章 总则 第二章 总经理层人员的组成及任免 第四条 公司总经理层设总经理一名，副总经理若干名，财务总监一名。总 经理对公司董事会负责，全面负责公司日常经营管理。 公司可以根据生产经营发展的需要，增设其他高级管理人员。 第五条 总经理由董事长提名，经董事会提名委员会审查后，由董事会决定 聘任或者解聘；公司副总经理、财务总监等高级管理人员，由总经理提名，董事 会决定聘任或者解聘。 董事可受聘兼任 ...

深圳市卫光生物制品股份有限公司 董事会提名委员会工作细则 第一章 总 则 第一条 为规范深圳市卫光生物制品股份有限公司（以下称公司）董事会提 名委员会的职责权限，规范提名委员会内部运作程序，完善公司治理结构，根据 《中华人民共和国公司法》《上市公司治理准则》《上市公司独立董事管理办法》 《深圳市卫光生物制品股份有限公司章程》（以下称《公司章程》）及其他有关规 定，特制定本细则。 第二条 董事会提名委员会（下称提名委员会或委员会）是董事会按照《公 司章程》设立的专门委员会，主要负责拟定董事、高级管理人员的选择标准和程 序，对董事、高级管理人员人选及其任职资格进行遴选、审核并提出建议。 第二章 人员组成 第三条 提名委员会成员由 3 名董事组成，其中包括 2 名独立董事。 第四条 提名委员会委员（下称委员）由董事长、三分之一以上董事或者二 分之一以上独立董事提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名，负责主持委员会工作；主任 委员由委员选举产生，主任委员需选举独立董事担任。 第六条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，自动失去 ...

深圳市卫光生物制品股份有限公司 董事会议事规则 第一章 总 则 第一条 为规范深圳市卫光生物制品股份有限公司（以下简称公司）的董事 会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规 范运作和科学决策水平，根据《中华人民共和国公司法》（以下简称《公司法》） 《中华人民共和国证券法》（以下简称《证券法》）等有关法律法规及《公司章 程》有关规定，制订本规则。 第二条 董事会依照法律、行政法规、《公司章程》及本规则的相关规定行 使职权，并对股东会负责。 第三条 董事会下设董事会办公室，处理董事会日常事务。 第二章 董事会和董事长的职权 第四条 董事会行使下列职权： （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公 司形式的方案； （七）在股东会授权范围内，决定公司对外投资、收购出售资产、资产抵押、 财务资助、对外担保事项、委托理财、关联交易、对外捐赠等事项； （八）决定公司内部管理机构的设置； （九）聘任或者解聘公司总经理、董事会秘书及其他高级管理人员，并决定 其报酬事项和奖惩事项；根据总经理的提名，聘任或者解聘公司副总经理、财务 负责人等高级管理人员，并决定其报酬事项和奖惩事 ...